Lead sponsor
Nanexa AB
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
1
Trials led
0
Ongoing
12
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Trials by status
Completed
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2DBMI 18.5-35Ph 1Completed12